chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My left arm kind of itched, burning in the left arm," lasted a little bit"  had a headache, joint pain, "muscle pain is what is working on me a lot."; My left arm kind of itched, burning in the left arm," lasted a little bit"  had a headache, joint pain, "muscle pain is what is working on me a lot."; My left arm kind of itched, burning in the left arm," lasted a little bit"  had a headache, joint pain, "muscle pain is what is working on me a lot."; My left arm kind of itched, burning in the left arm," lasted a little bit"  had a headache, joint pain, "muscle pain is what is working on me a lot."; I still have pain in my crotch and legs; Still having the diarrhea and the muscle pain; I had a bump on my arm and it hurt to lift my arm; This is a spontaneous report from a contactable consumer or other non health care professional (patient). This consumer reported for herself that a 65-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot number was EW0164 and expiration date was not reported), via an unspecified route of administration, administered in right arm on 16Apr2021 at 09:30 hours (Age at vaccination was 65 year) as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Previously patient took shingles shot and it did the same thing to her. On an unspecified date, patient experienced left arm kind of itched, burning in the left arm, lasted a little bit, headache, joint pain, muscle pain was what was working on her a lot, Patient Still having the diarrhea and the muscle pain, Patient still had pain in her crotch and legs and She had a bump on her arm and it hurt to lift her arm. Patient suppose to get her another one shot on 07May2021. The outcome of events was unknown.  No follow-up attempts are needed. No further information is expected.
After Jan 8th vaccine, developed vertigo/dizziness(Room Spinning) w/ nausea and severe muscle aches on  Jan 22 (2 weeks after vaccination date)lasted 3 days after Feb 5th vaccine developed vertigo/dizziness(Room Spinning)w/nausea and severe muscle aches on Feb 26th(3 weeks after vaccination date) Still presently  having symptoms(currently on day 7).
PAIN ALONG SOME OF THE VEINS IN LEGS; HEAVY FEELING IN LEGS; This spontaneous report received from a physician concerned a 67 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: varicose vein. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029, and expiry: UNKNOWN) dose was not reported, administered on 09-MAR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 01-JUN-2021, the patient experienced pain along some of the veins in legs. On 01-JUN-2021, the patient experienced heavy feeling in legs. Laboratory data (dates unspecified) included: Venous Doppler (NR: not provided) No blood clot or no DVT (deep vein thrombosis). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from pain along some of the veins in legs, and heavy feeling in legs on AUG-2021. This report was non-serious.
Beginning approximately one week after injection, I began having dry mouth.  Sometimes it is worse than others, but drinking large quantities of water doesn?t make it better. I?ve also been having a slight metallic/bitter taste in my mouth and on my lips for about 2 weeks.
This spontaneous report as received from a pharmacist via field representative refers to a patient of unknown age and unknown gender. The patient's pertinent medical history was not reported. On an unknown date the patient was vaccinated with ZOSTAVAX (Dose/Frequency: Unspecified, Therapy Route: Unspecified). Concomitant medications were unspecified. On an unknown date the patient experienced welt at the injection site after the administration of ZOSTAVAX. The patient sought medical attention by contacting the pharmacist. The pharmacist advised the patient to use ice compresses on the site and to take BENADRYL. The outcome of injection site reaction was reported as resolved in 1 day. The causality was not reported. Additional information has been requested.
Information has been received from a medical assistant referring to multiple patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with improperly stored GARDASIL 9 (lot # L048459, expiration date 22-FEB-2018; lot # M004116, expiration date 12-OCT-2017; lot # M007728, expiration date 21-MAR-2018; lot # L045700, expiration date 22-FEB-2018; dose and route not reported). The doses of vaccine were improperly stored at 60 degree Fahrenheit for 25 minutes. Data logger was not involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a pharmacist refers to a 6 year old male patient. Patient's pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/ allergies were reported. On 25-FEB-2015, the patient was vaccinated with ZOSTAVAX (strength, dosing details, anatomical location, lot# and expiration date were unknown). The reporting pharmacist stated that the patient's leg at the injection site hurt for 5 to 7 days after vaccination (approximately in FEB-2015). Four weeks after the vaccination, pharmacist was notified from the healthcare provider that the patient was inadvertently given ZOSTAVAX instead of VARIVAX. No medical attention was sought for the event. The outcome of injection site pain was unknown, causality assessment was not provided. No product quality complaint was involved. This report is linked with case# 1611USA000093, due to same reporter source. Additional information has been requested.
about 6 hours after recieving 3rd dose of COVID-Moderna, patient had outbreak of hives diffusely on body with itching and swelling.  No change to breathing.   Patient treated with ibuprofen and loratadine over the counter medications.   Hives improved but not completely resolved at time of clinic appointment.  No other symptoms identified.
Apnea with shock like state (ashen color, cool moist skin, decreased muscle tone) gradually recovered over the course of 1 hr. Had onset at 3 hrs after DTP/OPV
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 03-APR-2014, the patient was vaccinated with VARIVAX (Merck) (dose strength and route was not reported) (lot # J004159 and expiry date: 08-APR-2015) which was improperly stored. Primary reporter was reporting excursion of 6 F since 01-JUN-2013 (confirmed date) affecting VARIVAX (Merck), nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported for VARIVAX (Merck). This is one of the several reports from the same reporter. Additional information has been requested.
Pt. reports that he developed R shoulder pain about 4 days after receiving flu shot on 8/24/18. He first had the typical muscle pain around injection site that went away in a couple of days, then the R shoulder joint started hurting severely. He c/o stiffness, limited ROM due to pain and stiffness. Most of all it bothers him when he sits still or tries to sleep, it just throbs. He has not previously had any problems with the R shoulder. The pain and discomfort have not improved in the 10 weeks since it started. He has taken ibuprofen but it did not help. Heat, ice, voltaren gel were also ineffective. Pt. was now referred to orthopedics for steroid injection to the R shoulder joint, and to physical therapy.
Pt vaccinated with DTP approx 6 hrs after 5 immunization, pt experienced tonic clonic seizure; recovered.
It was reported in a published article that a 7 year old male experienced fever and severe herpes zoster pain with facial rash and was hospitalized who was vaccinated with VARIVAX (Merck) 6 years previously. The varicella-zoster virus (VZV) vaccine strain may reactivate to cause herpes zoster. Limited data suggest that the risk of herpes zoster in vaccinated children could be lower than in children with naturally acquired varicella. The authors examine incidence trends, risk, and epidemiologic and clinical features of herpes zoster disease among children and adolescents by vaccination status. Population-based active surveillance was conducted among 20 year old residents from 2000 through 2006, structured telephone interviews collected demographic, varicella vaccination and disease histories, and clinical information. From 2000 to 2006, the incidence of herpes zoster among children less than 10 years of age declined by 55%, from 42 cases reported in 2000 (74.8/100,000 persons; 95% confidence interval [95% CI]: 55.3-101.2) to 18 reported in 2006 (933.3/100,000; 95% CI: 20.9-52.8; P less than 0.001). During the same period, the incidence of herpes zoster among 10- to 19-year-old increased by 63%, from 35 cases reported in 2000 (59.5/100,000 persons; 95% CI: 42.7-82.9) to 64 reported in 2006 (96.7/100,000; 95% CI: 75.7-123.6; P less than 0.02). Among children aged less than 10 years, those with a history of varicella vaccination had a 4 to 12 times lower risk for developing herpes zoster compared with children with history of varicella disease. Varicella vaccine substantially decreases the risk of herpes zoster among vaccinated children and its widespread use will likely reduce overall herpes zoster burden. The increase in herpes zoster incidence among 10- to 19-year-olds could be confidently explained and needs to be confirmed from other data sources. The patient was a healthy 7-year-old boy who was vaccinated 6 years previously and had no history of varicella. He was admitted with fever and severe herpes zoster pain with facial rash. Overall, the rate of herpes zoster-related hospitalization per 100,000 population aged, 20 years was 0.6 (95% CI: 0.25-146), and the rate of hospitalization per 1000 herpes zoster cases was 10.9 (95% CI: 4.5-26.2). No further information is available.
Information has been received from a health professional and a licensed professional nurse concerning a 65 year old female with an allergy to codeine, hypertension and hyperlipidaemia who on 09-OCT-2006 at 1400 was vaccinated subcutaneously in the left upper arm with a first dose of Pneumovax 23 (lot #651330/1048P).  Concomitant therapy included ezetimibe (+) simvastatin (MSD), 10-20 tablet, total daily dose not reported, AVALIDE, SYNTHROID, CELEXA and COUMADIN.  There was no illness at the time of vaccination.  On 11-OCT-2006 at 1000 the patient experienced an injection site reaction with warmth, tenderness, and erythema, and a "cellulitis impression".  Medical attention at the doctor's office was sought.  The patient was treated with KEFLEX and warm compresses.  No lab studies were performed.  The patient did not return for further treatment.  On 13-OCT-2006 the patient recovered.  Follow-up information has been received from a nurse who expressed concern that three patients in the same week had these reactions and said that they were no longer giving Pneumovax 23 vaccinations.  The nurse said that she will await results of whatever investigation will be done.  Follow-up information has been received.  The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory.  The lot met the requirements of the agency and was released by the regulatory agency.  No further information is expected.
This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not provided. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (strength, dose, route, lot number, expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced an unspecified adverse reaction after receiving a dose of ZOSTAVAX. The outcome of the adverse reaction was not known at the time of reporting. The causal relationship of the adverse reaction and the ZOSTAVAX vaccine was not provided. This is one of two reports from the same source. Additional information is not expected as no contact details were provided. Sender's Comments: US-009507513-1706USA004395.
Pt recvd a series of 3 Engerix-B on 18SEP90, 18OCT90 & 20MAR91 for immun; NOV91 pt was tested was found to be non-immune; Reporter indicated that pt was scheduled to receive a booster dose on 20NOV91;
Stability/expiration date 9/30/22 - administered 10/11/22.
Red and swollen about 3 inches in diameter with a raised lump, used ice to reduce swelling. Down to dime size on 05.18.14. As of 05.20.14 lump still exists under skin to touch.
Patient developed a rash one day after receiving third dose. The rash is on her hands, forearms, back, legs and stomach. Patient has tried Allegra with no relief and Benadryl with some relief.
Develope headache with in 5 hours of receiving vaccine, Within 18 hours developed generalized rash of the upper torso and face. Self treated with over the counter benadryl capsules and cortaid creme about three days after symptoms appeared. Symptoms cleared in one week (7 days) after appearance. Did not seek professional medical care.
Right arm swelling, redness and warmth. Motrin 150mg q6h prn, Benadryl 12.5mg q6h prn.
102 fever; aching arm; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (102 fever) and PAIN IN EXTREMITY (aching arm) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On 28-Jul-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 29-Jul-2022, the patient experienced PYREXIA (102 fever) and PAIN IN EXTREMITY (aching arm). At the time of the report, PYREXIA (102 fever) and PAIN IN EXTREMITY (aching arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 102.     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       No concomitant medication information provided. It was reported that patient had the vaccine yesterday and now had a 102 fever and aching, further asked about contiguous as patient work with pregnant women. No treatment information provided
My friend got them three more times after being vaccinated/ Suspected vaccination failure; My friend got them three more times; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The case was reported by patient's friend. The age at vaccination was not reported. The patient got shingles three more times after being vaccinated, so they could save it. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.
about 23hr p/vax neck, back, arms & leg muscles were very weak & sore;PAP taken but gave no relief;muscle pain & weakness cont wrists, feet & ankles swelling when ASA wears off;
I noticed when I picked my son up he had a rash on his leg at the sight of the injection and the rash was running down into his inner thigh. He has a lump at the sight of the injection as well. He has had normal BMs and is potty trained but he has a very bad rash on his butt crack and like big red bumps on his butt cheeks that are on the right side (same sight as the injection).
aching all over her body; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (aching all over her body) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, the patient experienced PAIN (aching all over her body). At the time of the report, PAIN (aching all over her body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Pt called day after administration of vaccine with pain from elbow to shoulder - painful to move or touch. Followed up 1/31/15 - pt symptoms resolving and pain decreasing.
makes me sick; Initial information received on 11-Dec-2020 regarding an unsolicited valid non-serious case was received from a consumer (patient) via social media.  This case involves an unknown age patient who reported illness (makes me sick), while he/she received vaccine Influenza Vaccine.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect Influenza Vaccine produced by unknown manufacturer lot number not reported via unknown route in unknown administration site, for Prophylactic vaccination.  On an unknown date, the patient reported that the vaccine made him/her sick (Illness) (Unknown latency) following the administration of Influenza Vaccine.   It was reported that, the reporter did not take the shot because it made him/her sick every time and had not had the flu since 1986.  No laboratory data was reported.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as Unknown.  No further information was reported.
Information has been received from a woman in a doctor's office concerning a 4-year-old white female with a recent shingles exposure who on 06-Jan-2000 was vaccinated with a first dose of varicella virus vaccine live. The reporter indicated that the patient's mother had shingles on 01-Nov-2003. On 10-Nov-2003 the patient broke out with 50 pox. It was noted that the patient "recovered fine." No further information is expected.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2012, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Initial report received on 18 April 2008 from a nurse in the USA. A 20 year old female patient received on 09 April 2008 a left deltoid intramuscular injection of ADACEL (lot # C2936BA), a left deltoid intramuscular injection of IPOL (A0342-2) and a right deltoid intramuscular injection of a HEPATITIS A vaccine (GSK, lot # AHAVB224CA). The patient's medical history included no known allergies and hypothyroidism and concomitant medication was LEVOTHYROXINE. The patient had no illness at the time of vaccination. On 18 April 2008, nine days post-vaccination, the patient developed a sore left arm. There were no signs and symptoms of infection and no decreased range of motion. The recommended treatment was "OTC" pain medication and warm packs. At the time of reporting, 18 April 2008, the patient had not recovered.
Increasing redness at injection site with itching then tiny, itchy blisters formed. This lasted for two weeks. I treated it with OTC cortisone cream. That site by injection cleared up and now it has moved (the tiny, itchy blisters) to under my left arm with redness since August 25, 2016. I'm treating that with OTC cortisone. I had a flu shot given at the same time as the Shingles vaccine at the Pharmacy.
Pt is here today for COVID-19 immunization per federal guidelines/written order. See immunization activity for details. Pt was observed post-immunization for a minimum of 15 minutes with evidence of dizziness and nausea, heart palpitations.  Anaphylaxis Management Standing Order protocol initiated.  Physician/APP notified of patient condition.   Additional orders received: none per Dr.  COVID-19 (MRNA) VACCINE Allergen added to patient's Allergies. VAERS reporting completed as appropriate.     1640:  At end of 15 minute observation, patient complained of sudden onset dizziness, flushing, palpitations and nausea.  Immediately brought to exam room and patient began to dry heave (no actual emesis).  Cool cloth applied to neck.   VITALS:  BP 153/81, Pulse "166" via dynamap, but manual recheck was 84.  Patient stated symptoms starting to resolve.   1645:  Dr. came up from office to evaluate patient.  Manual pulse check 80.  No shortness of breath or throat tightening.  No chest tightness, no rash, no itching.  Patient states symptoms much improved.  Per Dr. , no additional orders, but observe for 30 additional minutes.   1655:  VITALS:  BP 161/77, Pulse 67 via dynamap.  Patient states she feels much better.  Discussed precautions prior to next vaccine (eating and drinking) and consideration of taking oral Benadryl prior to next vaccine (using caution if driving).  Also advised she can take a dose of oral Benadryl this evening (has history of bee sting allergy and carries Epi Pens).  Verbalized understanding.  Patient going home from clinic and accompanied by mom.     1705:  Patient states she feels "100% better," and would like to leave.  Has been 25 minutes since reaction started.  Patient discharged ambulatory.  VAERS submitted.   COVID-19 post-vaccination Patient Instructions added to After Visit Summary for patient to review in her MyChart account.
Around 4pm, I started feeling nauseous, along with stomach pain, chills, headache, diarrhea and two of my fingers went numb. I went to the ER on Friday and they did a COVID test, bloodwork and gave me fluids via IV. I was given meds for my stomach pain, but they couldn't find anything so I was sent home. I ended up losing 10lbs and it took about 2 weeks to recover completely.